Hologic stock gains 2% on better than expected Q4 results

Hologic (NASDAQ:) shares rose more than 2% after-hours following the company’s reported Q4 results, with EPS of $0.89 coming in better than the consensus estimate of $0.84. Revenue decreased 0.8% year-over-year to $945.3 million, beating the consensus estimate of $940.03M.

“Hologic delivered remarkable fiscal 2023 results extending our track record of strong performance with another solid quarter of growth in our fourth quarter. Each one of our divisions grew double digits organically in the quarter and for the full year excluding the impact of COVID,” said CEO Steve MacMillan.

For Q1/24, the company expects EPS in the range of $0.92-$0.97, compared to the consensus of $0.94, and revenue in the range of $960-$985M, compared to the consensus of $1.017 billion.

For the full year, the company anticipates EPS of $3.90-$4.10, compared to the consensus of $3.90, and revenue of $3.92-$4.02B, compared to the consensus of $4.023B.